Identifying the natural products in the treatment of atherosclerosis by increasing HDL-C level based on bioinformatics analysis, molecular docking, and in vitro experiment.
Atherosclerosis
Differential gene analysis
Genistein
High-density lipoprotein cholesterol
Molecular docking
PPI network analysis
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
19 Dec 2023
19 Dec 2023
Historique:
received:
26
08
2023
accepted:
23
11
2023
medline:
20
12
2023
pubmed:
20
12
2023
entrez:
20
12
2023
Statut:
epublish
Résumé
Previous studies have demonstrated that high-density lipoprotein cholesterol (HDL-C) plays an anti-atherosclerosis role through reverse cholesterol transport. Several studies have validated the efficacy and safety of natural products in treating atherosclerosis (AS). However, the study of raising HDL-C levels through natural products to treat AS still needs to be explored. The gene sets associated with AS were collected and identified by differential gene analysis and database query. By constructing a protein-protein interaction (PPI) network, the core submodules in the network are screened out. At the same time, by calculating node importance (Nim) in the PPI network of AS disease and combining it with Kyoto Encyclopedia of genes and genomes (KEGG) pathways enrichment analysis, the key target proteins of AS were obtained. Molecular docking is used to screen out small natural drug molecules with potential therapeutic effects. By constructing an in vitro foam cell model, the effects of small molecules on lipid metabolism and key target expression of foam cells were investigated. By differential gene analysis, 451 differential genes were obtained, and a total of 313 disease genes were obtained from 6 kind of databases, then 758 AS-related genes were obtained. The enrichment analysis of the KEGG pathway showed that the enhancement of HDL-C level against AS was related to Lipid and atherosclerosis, Cholesterol metabolism, Fluid shear stress and atherosclerosis, PPAR signaling pathway, and other pathways. Then we intersected 31 genes in the core module of the PPI network, the top 30 genes in Nims, and 32 genes in the cholesterol metabolism pathway, and finally found 3 genes. After the above analysis and literature collection, we focused on the following three related gene targets: APOA1, LIPC, and CETP. Molecular docking showed that Genistein has a good binding affinity for APOA1, CETP, and LIPC. In vitro, experiments showed that Genistein can up-regulated APOA1, LIPC, and CETP levels. Based on our research, Genistein may have the effects of regulating HDL-C and anti-atherosclerosis. Its mechanism of action may be related to the regulation of LIPC, CETP, and APOA1 to improve lipid metabolism.
Sections du résumé
BACKGROUND
BACKGROUND
Previous studies have demonstrated that high-density lipoprotein cholesterol (HDL-C) plays an anti-atherosclerosis role through reverse cholesterol transport. Several studies have validated the efficacy and safety of natural products in treating atherosclerosis (AS). However, the study of raising HDL-C levels through natural products to treat AS still needs to be explored.
METHODS
METHODS
The gene sets associated with AS were collected and identified by differential gene analysis and database query. By constructing a protein-protein interaction (PPI) network, the core submodules in the network are screened out. At the same time, by calculating node importance (Nim) in the PPI network of AS disease and combining it with Kyoto Encyclopedia of genes and genomes (KEGG) pathways enrichment analysis, the key target proteins of AS were obtained. Molecular docking is used to screen out small natural drug molecules with potential therapeutic effects. By constructing an in vitro foam cell model, the effects of small molecules on lipid metabolism and key target expression of foam cells were investigated.
RESULTS
RESULTS
By differential gene analysis, 451 differential genes were obtained, and a total of 313 disease genes were obtained from 6 kind of databases, then 758 AS-related genes were obtained. The enrichment analysis of the KEGG pathway showed that the enhancement of HDL-C level against AS was related to Lipid and atherosclerosis, Cholesterol metabolism, Fluid shear stress and atherosclerosis, PPAR signaling pathway, and other pathways. Then we intersected 31 genes in the core module of the PPI network, the top 30 genes in Nims, and 32 genes in the cholesterol metabolism pathway, and finally found 3 genes. After the above analysis and literature collection, we focused on the following three related gene targets: APOA1, LIPC, and CETP. Molecular docking showed that Genistein has a good binding affinity for APOA1, CETP, and LIPC. In vitro, experiments showed that Genistein can up-regulated APOA1, LIPC, and CETP levels.
CONCLUSIONS
CONCLUSIONS
Based on our research, Genistein may have the effects of regulating HDL-C and anti-atherosclerosis. Its mechanism of action may be related to the regulation of LIPC, CETP, and APOA1 to improve lipid metabolism.
Identifiants
pubmed: 38115108
doi: 10.1186/s12967-023-04755-7
pii: 10.1186/s12967-023-04755-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
920Subventions
Organisme : Science and Technology Commission of Shanghai Municipality
ID : 22010504300
Informations de copyright
© 2023. The Author(s).
Références
Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol. 2006;47(8 Suppl):C7–12.
pubmed: 16631513
doi: 10.1016/j.jacc.2005.09.068
Song T, Chen WD. Berberine inhibited carotid atherosclerosis through PI3K/AKTmTOR signaling pathway. Bioengineered. 2021;12(1):8135–46.
pubmed: 34592881
pmcid: 8806982
doi: 10.1080/21655979.2021.1987130
Fan J, Watanabe T. Atherosclerosis: known and unknown. Pathol Int. 2022;72(3):151–60.
pubmed: 35076127
doi: 10.1111/pin.13202
Ouimet M, Barrett TJ, Fisher EA. HDL and reverse cholesterol transport. Circ Res. 2019;124(10):1505–18.
pubmed: 31071007
pmcid: 6813799
doi: 10.1161/CIRCRESAHA.119.312617
Nasibova A. Generation of nanoparticles in biological systems and their application prospects. Adv Biol Earth Sci. 2023;82:140–6.
Jafarova AF, Ramazanli VN. Antibacterial characteristics of Ag nanoparticle extracted from olive leaf. Adv Biol Earth Sci. 2020;53:218–23.
Linton MF, Yancey PG, Tao H, Davies SS. HDL function and atherosclerosis: reactive dicarbonyls as promising targets of therapy. Circ Res. 2023;132(11):1521–45.
pubmed: 37228232
doi: 10.1161/CIRCRESAHA.123.321563
von Eckardstein A, Nordestgaard BG, Remaley AT, Catapano AL. High-density lipoprotein revisited: biological functions and clinical relevance. Eur Heart J. 2023;44(16):1394–407.
doi: 10.1093/eurheartj/ehac605
Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127–35.
pubmed: 21226578
pmcid: 3030449
doi: 10.1056/NEJMoa1001689
Khalilov R, Abdullayeva S. Mechanisms of insulin action and insulin resistance. Adv Biol Earth Sci. 2023;8(2):165–79.
Lakhdar M. The biological activities of flavonoids and plant cell wall polysaccharides: a minireview. Adv Biol Earth Sci. 2020;52:69–75.
Zhu Y, Ouyang Z, Du H, Wang M, Wang J, Sun H, et al. New opportunities and challenges of natural products research: when target identification meets single-cell multiomics. Acta Pharm Sin B. 2022;12(11):4011–39.
pubmed: 36386472
pmcid: 9643300
doi: 10.1016/j.apsb.2022.08.022
Ma S, Liu J, Li W, Liu Y, Hui X, Qu P, et al. Machine learning in TCM with natural products and molecules: current status and future perspectives. Chin Med. 2023;18(1):43.
pubmed: 37076902
pmcid: 10116715
doi: 10.1186/s13020-023-00741-9
Wang C, Niimi M, Watanabe T, Wang Y, Liang J, Fan J. Treatment of atherosclerosis by traditional Chinese medicine: questions and quandaries. Atherosclerosis. 2018;277:136–44.
pubmed: 30212682
doi: 10.1016/j.atherosclerosis.2018.08.039
Liu Q, Li J, Hartstone-Rose A, Wang J, Li J, Janicki JS, et al. Chinese herbal compounds for the prevention and treatment of atherosclerosis: experimental evidence and mechanisms. Evid Based Complement Alternat Med. 2015;2015:752610.
pubmed: 26089946
pmcid: 4451781
Okuyama H, Langsjoen PH, Hamazaki T, Ogushi Y, Hama R, Kobayashi T, et al. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Expert Rev Clin Pharmacol. 2015;8(2):189–99.
pubmed: 25655639
doi: 10.1586/17512433.2015.1011125
Ali AH, Younis N, Abdallah R, Shaer F, Dakroub A, Ayoub MA, et al. Lipid-lowering therapies for atherosclerosis: statins, fibrates, ezetimibe and PCSK9 monoclonal antibodies. Curr Med Chem. 2021;28(36):7427–45.
pubmed: 33655822
doi: 10.2174/0929867328666210222092628
Malekmohammad K, Sewell RDE, Rafieian-Kopaei M. Antioxidants atherosclerosis: mechanistic aspects. Biomolecules. 2019;9(8):301.
pubmed: 31349600
pmcid: 6722928
doi: 10.3390/biom9080301
Li TT, Wang ZB, Li Y, Cao F, Yang BY, Kuang HX. The mechanisms of traditional Chinese medicine underlying the prevention and treatment of atherosclerosis. Chin J Nat Med. 2019;17(6):401–12.
pubmed: 31262453
Wooller SK, Benstead-Hume G, Chen X, Ali Y, Pearl FMG. Bioinformatics in translational drug discovery. Biosci Rep. 2017;37(4):BSR20160180.
pubmed: 28487472
pmcid: 6448364
doi: 10.1042/BSR20160180
Jiashuo WU, Fangqing Z, Zhuangzhuang LI, Weiyi J, Yue S. Integration strategy of network pharmacology in traditional Chinese medicine: a narrative review. J Tradit Chin Med. 2022;42(3):479–86.
pubmed: 35610020
Nogales C, Mamdouh ZM, List M, Kiel C, Casas AI, Schmidt H. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol Sci. 2022;43(2):136–50.
pubmed: 34895945
doi: 10.1016/j.tips.2021.11.004
Pinzi L, Rastelli G. Molecular docking: shifting paradigms in drug discovery. Int J Mol Sci. 2019;20(18):4331.
pubmed: 31487867
pmcid: 6769923
doi: 10.3390/ijms20184331
Diboun I, Wernisch L, Orengo CA, Koltzenburg M. Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma. BMC Genom. 2006;7: 252.
doi: 10.1186/1471-2164-7-252
Gao SS, Sun JJ, Wang X, Hu YY, Feng Q, Gou XJ. Research on the mechanism of Qushi Huayu decoction in the intervention of nonalcoholic fatty liver disease based on network pharmacology and molecular docking technology. Biomed Res Int. 2020;2020:1704960.
pubmed: 33204683
pmcid: 7658690
doi: 10.1155/2020/1704960
YingHuang, Gao SS, Gong ZH, Li WJ, Xiao j, Sun JJ, et al. Mechanism of Sanhua decoction in the treatment of ischemic stroke based on network pharmacology methods and experimental verification. Biomed Res Int. 2022;2022:7759402.
pubmed: 35097126
Davis AP, Grondin CJ, Johnson RJ, Sciaky D, Wiegers J, Wiegers TC, et al. Comparative toxicogenomics database (CTD): update 2021. Nucleic Acids Res. 2021;49(D1):D1138–43.
pubmed: 33068428
doi: 10.1093/nar/gkaa891
Pinero J, Queralt-Rosinach N, Bravo A, Deu-Pons J, Bauer-Mehren A, Baron M, et al. DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes. Database. 2015;2015: bav028.
pubmed: 25877637
pmcid: 4397996
doi: 10.1093/database/bav028
Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D. GeneCards: integrating information about genes, proteins and diseases. Trends Genet. 1997;13(4):163.
pubmed: 9097728
doi: 10.1016/S0168-9525(97)01103-7
Amberger JS, Hamosh A. Searching online mendelian inheritance in man (OMIM): a knowledgebase of human genes and genetic phenotypes. Curr Protoc Bioinform. 2017;58(1):12.
doi: 10.1002/cpbi.27
Amberger JS, Bocchini CA, Schiettecatte F, Scott AF, Hamosh A. OMIM.org: online mendelian inheritance in man (OMIM(R)), an online catalog of human genes and genetic disorders. Nucleic Acids Res. 2015;43(Database issue):D789–98.
pubmed: 25428349
doi: 10.1093/nar/gku1205
Mitra-Ghosh T, Callisto SP, Lamba JK, Remmel RP, Birnbaum AK, Barbarino JM, et al. PharmGKB summary: lamotrigine pathway, pharmacokinetics and pharmacodynamics. Pharmacogenet Genom. 2020;30(4):81–90.
doi: 10.1097/FPC.0000000000000397
Zhou Y, Zhang Y, Lian X, Li F, Wang C, Zhu F, et al. Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. Nucleic Acids Res. 2022;50(D1):D1398–407.
pubmed: 34718717
doi: 10.1093/nar/gkab953
Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021;49(D1):D605–12.
pubmed: 33237311
doi: 10.1093/nar/gkaa1074
Xie R, Li B, Jia L, Li Y. Identification of core genes and pathways in melanoma metastasis via bioinformatics analysis. Int J Mol Sci. 2022;23(2):974.
doi: 10.3390/ijms23020794
Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):11.
doi: 10.1186/1752-0509-8-S4-S11
Chen YP, Wang KX, Cai JQ, Li Y, Yu HL, Wu Q, et al. Detecting key functional components group and speculating the potential mechanism of Xiao-Xu-Ming decoction in treating stroke. Front Cell Dev Biol. 2022;10: 753425.
pubmed: 35646921
pmcid: 9136080
doi: 10.3389/fcell.2022.753425
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25–9.
pubmed: 10802651
pmcid: 3037419
doi: 10.1038/75556
Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–7.
pubmed: 22455463
pmcid: 3339379
doi: 10.1089/omi.2011.0118
Burley SK, Berman HM, Duarte JM, Feng Z, Flatt JW, Hudson BP, et al. Protein Data Bank: a comprehensive review of 3D structure holdings and worldwide utilization by researchers, educators, and students. Biomolecules. 2022;12(10):1425.
pubmed: 36291635
pmcid: 9599165
doi: 10.3390/biom12101425
Yan D, Zheng G, Wang C, Chen Z, Mao T, Gao J, et al. HIT 2.0: an enhanced platform for herbal ingredients’ targets. Nucleic Acids Res. 2022;50(D1):D1238–43.
pubmed: 34986599
doi: 10.1093/nar/gkab1011
Duan H, Zhang Q, Liu J, Li R, Wang D, Peng W, et al. Suppression of apoptosis in vascular endothelial cell, the promising way for natural medicines to treat atherosclerosis. Pharmacol Res. 2021;168: 105599.
pubmed: 33838291
doi: 10.1016/j.phrs.2021.105599
Han S, Wu H, Li W, Gao P. Protective effects of genistein in homocysteine-induced endothelial cell inflammatory injury. Mol Cell Biochem. 2015;403(1–2):43–9.
pubmed: 25626894
doi: 10.1007/s11010-015-2335-0
Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, et al. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 2021;49(W1):W5–14.
pubmed: 33893803
pmcid: 8262709
doi: 10.1093/nar/gkab255
Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7: 42717.
pubmed: 28256516
pmcid: 5335600
doi: 10.1038/srep42717
von Eckardstein A. High density lipoproteins: is there a comeback as a therapeutic target? Prevention and treatment of atherosclerosis. In: Handbook of experimental pharmacology. Cham: Springer; 2021. p. 157–200.
Zhou R, Stouffer GA, Smith SC. Targeting the cholesterol paradigm in the risk reduction for atherosclerotic cardiovascular disease: does the mechanism of action of pharmacotherapy matter for clinical outcomes? J Cardiovasc Pharmacol Therap. 2021;26(6):533–49.
doi: 10.1177/10742484211023632
Ronsein GE, Vaisar T, Davidson WS, Bornfeldt KE, Probstfield JL, O’Brien KD, et al. Niacin increases atherogenic proteins in high-density lipoprotein of statin-treated subjects. Arterioscler Thromb Vasc Biol. 2021;41(8):2330–41.
pubmed: 34134520
pmcid: 8295224
doi: 10.1161/ATVBAHA.121.316278
Schmidt AF, Hunt NB, Gordillo-Maranon M, Charoen P, Drenos F, Kivimaki M, et al. Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. Nat Commun. 2021;12(1):5640.
pubmed: 34561430
pmcid: 8463530
doi: 10.1038/s41467-021-25703-3
Yamashita S, Ruscica M, Macchi C, Corsini A, Matsuzawa Y, Sirtori CR. Cholesteryl ester transfer protein: an enigmatic pharmacology—antagonists and agonists. Atherosclerosis. 2018;278:286–98.
pubmed: 30347344
doi: 10.1016/j.atherosclerosis.2018.09.035
Ginsberg HN, Hounslow NJ, Senko Y, Suganami H, Bogdanski P, Ceska R, et al. Efficacy and safety of K-877 (pemafibrate), a selective PPARalpha modulator, in European patients on statin therapy. Diabetes Care. 2022;45(4):898–908.
pubmed: 35238894
doi: 10.2337/dc21-1288
Bhale AS, Venkataraman K. Delineating the impact of pathogenic mutations on the conformational dynamics of HDL’s vital protein ApoA1: a combined computational and molecular dynamic simulation approach. J Biomol Struct Dyn. 2023. https://doi.org/10.1080/07391102.2023.2191131 .
doi: 10.1080/07391102.2023.2191131
pubmed: 36943736
Bhale AS, Venkataraman K. Leveraging knowledge of HDLs major protein ApoA1: structure, function, mutations, and potential therapeutics. Biomed Pharmacother. 2022;154: 113634.
pubmed: 36063649
doi: 10.1016/j.biopha.2022.113634
Zhong X, Yu J, Zhao D, Teng J, Jiao H. Association between serum apolipoprotein A1 and atrial fibrillation in the Chinese population: a case-control study. BMC Cardiovasc Disord. 2023;23(1):269.
pubmed: 37221493
pmcid: 10207818
doi: 10.1186/s12872-023-03283-y
Dalakoura-Karagkouni K, Tiniakou I, Zannis VI, Kardassis D. Using adenovirus-mediated gene transfer to study the effect of myeloperoxidase on plasma lipid levels, HDL structure and functionality in mice expressing human apoA-I forms. Biochem Biophys Res Commun. 2022;622:108–14.
pubmed: 35843089
doi: 10.1016/j.bbrc.2022.07.001
Nicholls SJ, Nelson AJ. CETP inhibitors: should we continue to pursue this pathway? Curr Atheroscler Rep. 2022;24(12):915–23.
pubmed: 36409446
doi: 10.1007/s11883-022-01070-2
Kosmas CE, DeJesus E, Rosario D, Vittorio TJ. CETP inhibition: past failures and future hopes. Clin Med Insights Cardiol. 2016;10:37–42.
pubmed: 26997876
pmcid: 4790583
doi: 10.4137/CMC.S32667
Xu M, Ng SS, Bray GA, Ryan DH, Sacks FM, Ning G, et al. Dietary fat intake modifies the effect of a common variant in the LIPC gene on changes in serum lipid concentrations during a long-term weight-loss intervention trial. J Nutr. 2015;145(6):1289–94.
pubmed: 25926410
pmcid: 4442119
doi: 10.3945/jn.115.212514
Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96(12):1221–32.
pubmed: 15976321
doi: 10.1161/01.RES.0000170946.56981.5c
Lee CJ, Park MS, Kim M, Ann SJ, Lee J, Park S, et al. CETP, LIPC, and SCARB1 variants in individuals with extremely high high-density lipoprotein-cholesterol levels. Sci Rep. 2019;9(1):10915.
pubmed: 31358896
pmcid: 6662756
doi: 10.1038/s41598-019-47456-2
Sharifi-Rad J, Quispe C, Imran M, Rauf A, Nadeem M, Gondal TA, et al. Genistein: an integrative overview of its mode of action, pharmacological properties, and health benefits. Oxid Med Cell Longev. 2021;2021:3268136.
pubmed: 34336089
pmcid: 8315847
doi: 10.1155/2021/3268136
Zheng S, Huang H, Li Y, Wang Y, Zheng Y, Liang J, et al. Yin-xing-tong-mai decoction attenuates atherosclerosis via activating PPARgamma-LXRalpha-ABCA1/ABCG1 pathway. Pharmacol Res. 2021;169: 105639.
pubmed: 33932607
doi: 10.1016/j.phrs.2021.105639